Vistagen Therapeutics, Inc. (VTGN) Eyes Breakthrough with Phase 3 Social Anxiety Trial

We recently compiled a list of the 13 Best Psychedelic Stocks to Invest in Now. Vistagen Therapeutics, Inc. is one of them.

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) is a late clinical-stage biopharmaceutical company developing neuroscience-focused therapies, including innovative intranasal pherine compounds. Its lead candidate, fasedienol, targets social anxiety disorder (SAD), with Phase 3 PALISADE-3 trial results expected in Q4 2025, a milestone that could be pivotal for the company. The business is also advancing other candidates, such as PH80 for menopausal hot flashes and itruvone for major depressive disorder, reflecting a diversified neuropsychiatric pipeline.

Recent efforts have focused on enhancing trial quality, regulatory communication, and research collaborations. Financially, the corporation remains strong with around $63 million in cash equivalents as of June 2025, supporting ongoing R&D initiatives. The mid-2025 appointment of a Chief Corporate Development Officer signals a strategic push toward business development and partnership expansion.

The upcoming PALISADE-3 readout is a key event for investors, given the substantial unmet need in SAD. Follow-up data from PALISADE-4 is also expected in the first half of 2026, indicating continued pipeline momentum. Vistagen Therapeutics, Inc. (NASDAQ:VTGN)’s emphasis on intranasal pherine compounds highlights a novel mechanism of action in treating neuropsychiatric conditions, setting it apart in a competitive landscape.

While the company faced operational challenges, including a trial site closure in Pennsylvania due to recruitment issues, overall clinical progress remains on track. Market sentiment shows rising technical momentum, though outcomes and competition present inherent risks.

While we acknowledge the potential of VTGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure. None.